EquityZen Growth Technology Fund LLC - Series 1087
Raised
$1M
Investors
19
Min Invest
$9,975
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 1087 is a Delaware-based pooled investment fund filed by EquityZen Advisors on December 15, 2021, raising $1.1M from 19 investors under Rule 506(b) and Section 3(c)(1) exemptions. The vehicle has a $10K minimum investment and is part of the EquityZen platform, which operates 1889+ related EDGAR entities focused on pre-IPO secondary market access.
This filing follows the standard EquityZen series SPV structure for pre-IPO investments, using the 506(b)/3(c)(1) exemption pattern typical of sub-100 investor funds. The $10K minimum represents a retail-accessible tier common to platform-operated secondary market vehicles, significantly lower than traditional institutional pre-IPO minimums.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Richard Thoms
Executive Officer · Salt Lake City, UT
Assure Fund Management II LLC
Director · Salt Lake City, UT
Philip Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
